Gilead's COVID-19 antiviral remdesivir-First COVID-19 treatment authorised for use in the EU

Key words

On 3 July 2020, the European Commission granted a conditional marketing authorisation for remdesivir, for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen.

This follows the recommendation of the CHMP from 25 June 2020 and allows the medicine to be marketed in the EU.

The invented name for the medicine is Veklury.

For more information, please see https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19#remdesivir-section